{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:31:48Z","timestamp":1792074708579,"version":"4.4.0"},"reference-count":53,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,4,12]],"date-time":"2016-04-12T00:00:00Z","timestamp":1460419200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2016,4,12]],"date-time":"2016-04-12T00:00:00Z","timestamp":1460419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Cancer Care"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1111\/ecc.12490","type":"journal-article","created":{"date-parts":[[2016,4,13]],"date-time":"2016-04-13T06:51:23Z","timestamp":1460530283000},"page":"e12490","source":"Crossref","is-referenced-by-count":16,"title":["The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey"],"prefix":"10.1155","volume":"26","author":[{"given":"T.","family":"Lebret","sequence":"first","affiliation":[{"name":"Departement d'Urologie; H\u00f4pital Foch; Suresnes France"},{"name":"Universit\u00e9 Versaille St Quentin en Yvelines; Versailles France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Casas","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u00eda M\u00e9dica; Hospital Universitario Virgen del Roc\u00edo; Sevilla Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cavo","sequence":"additional","affiliation":[{"name":"Departimento di Ematologia e Scienze Oncologiche; Universita di Bologna; Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.","family":"Woll","sequence":"additional","affiliation":[{"name":"University of Sheffield Academic Unit of Clinical Oncology; Weston Park Hospital; Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Deleplace","sequence":"additional","affiliation":[{"name":"Kantar Health France; Montrouge Cedex France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Amgen Ltd; Uxbridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Schoen","sequence":"additional","affiliation":[{"name":"Amgen (Europe) GmbH; Zug Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Jackisch","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology; Klinikum Offenbach Frauenklinik Starkenburgring; Offenbach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4,12]]},"reference":[{"key":"10.1111\/ecc.12490-BIB0001|ecc12490-cit-0001","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Annals of Oncology"},{"key":"10.1111\/ecc.12490-BIB0002|ecc12490-cit-0002","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1634\/theoncologist.2007-0245","article-title":"Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases","volume":"15","author":"Aapro","year":"2010","journal-title":"Oncologist"},{"key":"10.1111\/ecc.12490-BIB0004|ecc12490-cit-0004","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/ecc.12490-BIB0005|ecc12490-cit-0005","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/ecc.12490-BIB0006|ecc12490-cit-0006","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/cncr.11139","article-title":"Effectiveness and cost of bisphosphonate therapy in tumor bone disease","volume":"97","author":"Body","year":"2003","journal-title":"Cancer"},{"key":"10.1111\/ecc.12490-BIB0007|ecc12490-cit-0007","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-015-0716-7","article-title":"Health resource utilization associated with skeletal-related events: results from a retrospective European study","author":"Body","year":"2015","journal-title":"European Journal of Health Economics."},{"key":"10.1111\/ecc.12490-BIB0008|ecc12490-cit-0008","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1359\/jbmr.090810","article-title":"Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure","volume":"25","author":"Body","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1111\/ecc.12490-BIB0009|ecc12490-cit-0009","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2967\/jnumed.108.059584","article-title":"Economic evaluation of PET and PET\/CT in oncology: evidence and methodologic approaches","volume":"51","author":"Buck","year":"2010","journal-title":"Journal of Nuclear Medicine"},{"issue":"Suppl. 5","key":"10.1111\/ecc.12490-BIB0010|ecc12490-cit-0010","doi-asserted-by":"crossref","first-page":"v15","DOI":"10.1093\/annonc\/mdq160","article-title":"Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Cardoso","year":"2010","journal-title":"Annals of Oncology"},{"key":"10.1111\/ecc.12490-BIB0011|ecc12490-cit-0011","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treatment Reviews"},{"key":"10.1111\/ecc.12490-BIB0012|ecc12490-cit-0012","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","article-title":"Risks and benefits of bisphosphonates","volume":"98","author":"Coleman","year":"2008","journal-title":"British Journal of Cancer"},{"key":"10.1111\/ecc.12490-BIB0013|ecc12490-cit-0013","first-page":"1","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"00","author":"Coleman","year":"2014a","journal-title":"Annals of Oncology"},{"issue":"Suppl. 3","key":"10.1111\/ecc.12490-BIB0014|ecc12490-cit-0014","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014b","journal-title":"Annals of Oncology"},{"issue":"Suppl. 4","key":"10.1111\/ecc.12490-BIB0015|ecc12490-cit-0015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1634\/theoncologist.9-90004-28","article-title":"Safety of intravenous and oral bisphosphonates and compliance with dosing regimens","volume":"9","author":"Conte","year":"2004","journal-title":"Oncologist"},{"key":"10.1111\/ecc.12490-BIB0016|ecc12490-cit-0016","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","article-title":"Impact of skeletal complications on patients' quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Supportive Care in Cancer"},{"key":"10.1111\/ecc.12490-BIB0017|ecc12490-cit-0017","first-page":"341","article-title":"Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice","volume":"4","author":"Delea","year":"2006","journal-title":"The Journal of Supportive Oncology"},{"key":"10.1111\/ecc.12490-BIB0018|ecc12490-cit-0018","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00520-006-0203-x","article-title":"Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer","volume":"15","author":"Depuy","year":"2007","journal-title":"Supportive Care in Cancer"},{"key":"10.1111\/ecc.12490-BIB0021|ecc12490-cit-0021","unstructured":"European Association of Urology 2016 Oncology Guidelines: Prostate cancer [Online] http:\/\/uroweb.org\/guideline\/prostate-cancer\/"},{"key":"10.1111\/ecc.12490-BIB0019|ecc12490-cit-0019","unstructured":"European Medicines Agency 2015a PRAC recommends further measures to minimise risk of osteonecrosis of the jaw with bisphosphonate medicine http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2015\/03\/WC500184259.pdf"},{"key":"10.1111\/ecc.12490-BIB0020|ecc12490-cit-0020","unstructured":"European Medicines Agency 2015b XGEVA \u00ae (Denosumab) summary of product characteristics http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002173\/WC500110381.pdf"},{"key":"10.1111\/ecc.12490-BIB0022|ecc12490-cit-0022","unstructured":"European Society for Medical Oncology 2015 ESMO Clinical Practice Guidelines [Online]. European Society of Medical Oncology http:\/\/www.esmo.org\/education-research\/esmo-clinical-practice-guidelines.html"},{"key":"10.1111\/ecc.12490-BIB0023|ecc12490-cit-0023","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1111\/ecc.12490-BIB0024|ecc12490-cit-0024","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/annonc\/mdi818","article-title":"ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma","volume":"16","author":"Harrouseau","year":"2005","journal-title":"Annals of Oncology"},{"key":"10.1111\/ecc.12490-BIB0025|ecc12490-cit-0025","doi-asserted-by":"crossref","first-page":"A455","DOI":"10.1016\/j.jval.2011.08.1216","article-title":"Cost of skeletal-related events in patients with bone metastases to solid tumours based on the health resource utilisation collected in a prospective European multinational observational study","volume":"14","author":"Hechmati","year":"2011","journal-title":"Value in Health"},{"key":"10.1111\/ecc.12490-BIB0026|ecc12490-cit-0026","doi-asserted-by":"crossref","first-page":"abstr 9133.","DOI":"10.1200\/jco.2010.28.15_suppl.9133","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer","volume":"28","author":"Henry","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/ecc.12490-BIB0027|ecc12490-cit-0027","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/ecc.12490-BIB0028|ecc12490-cit-0028","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00520-013-2022-1","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with\u00a0advanced cancer: an analysis of data\u00a0from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Supportive Care in Cancer"},{"key":"10.1111\/ecc.12490-BIB0029|ecc12490-cit-0029","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jbo.2014.04.001","article-title":"Health resource utilization associated with skeletal-related events in patients with bone metastases: results from a multinational retrospective - prospective observational study - a cohort from 4 European countries","volume":"3","author":"Hoefeler","year":"2014","journal-title":"Journal of Bone Oncology"},{"key":"10.1111\/ecc.12490-BIB0030|ecc12490-cit-0030","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/030089160909500304","article-title":"Multidisciplinary approach to the treatment of bone metastases: Osteo-Oncology Center, a new organizational model","volume":"95","author":"Ibrahim","year":"2009","journal-title":"Tumori"},{"key":"10.1111\/ecc.12490-BIB0031|ecc12490-cit-0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/030089161309900101","article-title":"Metastatic bone disease in the era of bone-targeted therapy: clinical impact","volume":"99","author":"Ibrahim","year":"2013","journal-title":"Tumori"},{"key":"10.1111\/ecc.12490-BIB0032|ecc12490-cit-0032","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clinical Proceedings"},{"key":"10.1111\/ecc.12490-BIB0033|ecc12490-cit-0033","first-page":"317","article-title":"The cost of treating skeletal-related events in patients with prostate cancer","volume":"14","author":"Lage","year":"2008","journal-title":"American Journal of Managed Care"},{"key":"10.1111\/ecc.12490-BIB0034|ecc12490-cit-0034","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3816\/SCT.2007.n.003","article-title":"Treatment of bone metastases and bone pain with bisphosphonates","volume":"4","author":"Lipton","year":"2007","journal-title":"Supportive Cancer Therapy"},{"issue":"Suppl. 2","key":"10.1111\/ecc.12490-BIB0035|ecc12490-cit-0035","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1053\/j.seminoncol.2010.10.002","article-title":"Implications of bone metastases and the benefits of bone-targeted therapy","volume":"37","author":"Lipton","year":"2010","journal-title":"Seminars in Oncology"},{"key":"10.1111\/ecc.12490-BIB0036|ecc12490-cit-0036","doi-asserted-by":"crossref","first-page":"162","DOI":"10.6004\/jnccn.2010.0012","article-title":"NCCN clinical practice guidelines in oncology: prostate cancer","volume":"8","author":"Mohler","year":"2010","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10.1111\/ecc.12490-BIB0037|ecc12490-cit-0037","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00520-013-1755-1","article-title":"Reducing the burden of bone metastases: current concepts and treatment options","volume":"21","author":"Moos","year":"2013","journal-title":"Supportive Care in Cancer"},{"key":"10.1111\/ecc.12490-BIB0039|ecc12490-cit-0039","unstructured":"National Comprehensive Cancer Network 2016 http:\/\/www.nccn.Guidelinesorg\/professionals\/physician_gls\/f_guidelines.asp#site"},{"key":"10.1111\/ecc.12490-BIB0040|ecc12490-cit-0040","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","article-title":"Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007)","volume":"184","author":"Norgaard","year":"2010","journal-title":"Journal of Urology"},{"key":"10.1111\/ecc.12490-BIB0041|ecc12490-cit-0041","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/ecc.12490-BIB0042|ecc12490-cit-0042","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clon.2012.09.001","article-title":"Nasty or NICE? Findings from a UK survey to evaluate the impact of the National Institute for Health and Clinical Excellence (NICE) clinical guidelines on the management of prostate cancer","volume":"25","author":"Payne","year":"2013","journal-title":"Clinical Oncology (Royal College of Radiologists)"},{"key":"10.1111\/ecc.12490-BIB0043|ecc12490-cit-0043","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2354.2009.01135.x","article-title":"The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain","volume":"19","author":"Pockett","year":"2010","journal-title":"European Journal of Cancer Care"},{"key":"10.1111\/ecc.12490-BIB0044|ecc12490-cit-0044","doi-asserted-by":"crossref","first-page":"502","DOI":"10.6004\/jnccn.2014.0055","article-title":"Advances in supportive care for multiple myeloma","volume":"12","author":"Raje","year":"2014","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10.1111\/ecc.12490-BIB0045|ecc12490-cit-0045","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1111\/ecc.12490-BIB0046|ecc12490-cit-0046","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3816\/CGC.2007.n.022","article-title":"Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases","volume":"5","author":"Saad","year":"2007a","journal-title":"Clinical Genitourinary Cancer"},{"key":"10.1111\/ecc.12490-BIB0047|ecc12490-cit-0047","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007b","journal-title":"Cancer"},{"key":"10.1111\/ecc.12490-BIB0048|ecc12490-cit-0048","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the\u00a0treatment of bone metastases in\u00a0patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/ecc.12490-BIB0049|ecc12490-cit-0049","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/ecc.12490-BIB0050|ecc12490-cit-0050","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17474086.2013.874943","article-title":"Management of bone disease in multiple myeloma","volume":"7","author":"Terpos","year":"2014","journal-title":"Expert Review of Hematology"},{"key":"10.1111\/ecc.12490-BIB0051|ecc12490-cit-0051","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"10.1111\/ecc.12490-BIB0500|ecc12490-cit-0500","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Van Poznak","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/ecc.12490-BIB0052|ecc12490-cit-0052","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","article-title":"Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions","volume":"42","author":"Weinfurt","year":"2004","journal-title":"Medical Care"},{"key":"10.1111\/ecc.12490-BIB0053|ecc12490-cit-0053","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Annals of Oncology"},{"key":"10.1111\/ecc.12490-BIB0054|ecc12490-cit-0054","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Annals of Internal Medicine"}],"container-title":["European Journal of Cancer Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fecc.12490","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fecc.12490","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ecc.12490\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:09:53Z","timestamp":1671541793000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ecc.12490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,12]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"URL":"https:\/\/doi.org\/10.1111\/ecc.12490","archive":["Portico"],"relation":{},"ISSN":["0961-5423"],"issn-type":[{"value":"0961-5423","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4,12]]}}}